Hepatotoxicity due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical centre

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 7, 2013, Pages 934-939

  Shu, C C ^a,b   Lee, C H ^c   Lee, M C ^c   Wang, Jann Yuan ^a   Yu, C J ^a   Lee, L N ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Anti tuberculosis treatment; Hepatotoxicity; Isoniazid; Pyrazinamide; Rifampicin; Time dependent Cox regression

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INCIDENCE; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; TAIWAN; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAIWAN; TIME FACTORS; TRANSAMINASES; TUBERCULOSIS, PULMONARY;

EID: 84878938023     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0782     Document Type: Article

References (34)

1. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012. http://apps.who.int/iris/ bitstream/10665/75938/1/9789241564502-eng.pdf Accessed April 2013.
2. Albert R K, Iseman M, Sbarbaro J A, et al. Monitoring patients with tuberculosis for failure during and after treatment. Am Rev Respir Dis 1976; 114: 1051-1060.
3. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
4. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
5. Yew W W, Leung C C. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707. (Pubitemid 44581433)
6. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52: 1-77.
7. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477. (Pubitemid 37363354)
8. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
9. Huang Y S, Chern H D, Su W J, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
10. Wang J Y, Hsueh P R, Jan I S, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
11. van den Brande P, van Steenbergen W, Vervoort G, et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152: 1705-1708.
12. Shakya R, Rao B S, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079. (Pubitemid 38657755)
13. Wong W M, Wu P C, Yuen M F, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
14. Ungo J R, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
15. Ozick L A, Jacob L, Comer G M, et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 1995; 90: 1978-1980.
16. Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculosis therapy. Am J Respir Crit Care Med 2012; 185: 653-659.
17. Theron G, Peter J, van Zyl-Smit R, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184: 132-140.
18. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
19. Luh K-T, Chiang C-Y, Lee J-J, et al. Taiwan guidelines for TB diagnosis and treatment. 4th ed. Taipei, Taiwan: Center for Disease Control, Executive Yuan, 2011.
20. Shu C C, Wang J T, Lee C H, et al. Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculosis treatment: a case control study. BMC Infect Dis 2010; 10: 48.
21. Snider G L, Doctor L, Demas T A, et al. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 1971; 103: 625-640.
22. Lin J W, Chang Y C, Li H Y, et al. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care 2009; 32: 2294-2296.
23. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
24. Cruz-Hervert L P, Garcia-Garcia L, Ferreyra-Reyes L, et al. Tuberculosis in ageing: high rates, complex diagnosis and poor clinical outcomes. Age Ageing 2012; 41: 488-495.
25. Wang J Y, Liu C H, Hu F C, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011; 62: 448-455.
26. Younossian A B, Rochat T, Ketterer J P, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26: 462-464. (Pubitemid 41264210)
27. Solangi G A, Zuberi B F, Shaikh S, et al. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. J Coll Physicians Surg Pak 2004; 14: 136-138. (Pubitemid 38967664)
28. Brewer T F, Choi H W, Seas C, et al. Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment. PLoS ONE 2011; 6: e25861.
29. Schenker S, Martin R R, Hoyumpa A M. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-1105.
30. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018. (Pubitemid 29143893)
31. Fountain F F, Tolley E, Chrisman C R, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123. (Pubitemid 40994462)
32. Sulkowski M S, Thomas D L, Chaisson R E, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80. (Pubitemid 30038386)
33. Her M, Lee Y, Jung E, et al. Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int 2011; 31: 79-84.
34. Khokhar O S, Lewis J H. Hepatotoxicity of agents used in the management of inflammatory bowel disease. Dig Dis 2010; 28: 508-518.